Drug Trial Radar · NCT00105313
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Last checked: Nov 20, 2026Latest source record: Jun 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 2005
Primary completion
Not stated
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
Conditions
- Lymphoma
- Leukemia
- Cancer
Interventions
MEDI-507Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD) or the optimal biological dose
- (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with
- CD-2 positive lymphoproliferative disorders.
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
USC/Norris Cancer Center
Los Angeles, California
Yale Cancer Center
New Haven, Connecticut
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc
Tampa, Florida
University of Maryland School of Medicine, Greenebaum Cancer Center
Baltimore, Maryland
Tufts New England Medical Center
Boston, Massachusetts
Washington University
St Louis, Missouri
Nevada Cancer Institute
Las Vegas, Nevada
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Kimmel Cancer Center, Thomas Jefferson University
Philadelphia, Pennsylvania
M.D. Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.